Guangshengtang announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., a holding subsidiary of the company's innovative drug, is carrying out a randomized, double-blind, placebo-controlled phase II clinical trial of the GST-Peak-Triple full oral regimen to treat patients with chronic hepatitis B. Recently, participants in the first trial were successfully enrolled and administered.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.